Sustained Clinical Response and High Infliximab Survival in Psoriatic Arthritis Patients: A 3-year Long-Term Study

Seminars in Arthritis and Rheumatism

Volumn 37, Issue 5, 2008, Pages 293-298

  Voulgari, Paraskevi V ^a   Venetsanopoulou, Aliki I ^a   Exarchou, Sofia A ^a   Alamanos, Yannis ^b   Tsifetaki, Niki ^c   Drosos, Alexandros A ^a  

^a UNIVERSITY OF IOANNINA   (Greece)

^b UNIVERSITY OF PATRAS   (Greece)

^c UNIVERSITY OF IOANNINA   (Greece)

Author keywords

efficacy; infliximab survival; psoriasis; psoriatic arthritis; toxicity

Indexed keywords

ANTINUCLEAR ANTIBODY; C REACTIVE PROTEIN; CARDIOLIPIN ANTIBODY; CYCLOSPORIN A; DISEASE MODIFYING ANTIRHEUMATIC DRUG; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; PREDNISONE;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DISEASE ACTIVITY; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG WITHDRAWAL; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HUMAN; LOW DRUG DOSE; MALE; OPEN STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; PSORIATIC ARTHRITIS; SURVIVAL RATE; SURVIVAL TIME; TREATMENT DURATION; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; ARTHRITIS, PSORIATIC; DELAYED-ACTION PREPARATIONS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; GREECE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; PREVALENCE; PROSPECTIVE STUDIES; SURVIVAL RATE; TIME FACTORS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 40749098959     PISSN: 00490172     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.semarthrit.2007.07.003     Document Type: Article

References (40)

1. Shbeeb M., Uramoto K.M., Gibson L.E., O'Fallon W.M., and Gabriel S.E. The epidemiology of psoriatic arthritis in Olmsted County. Minnesota, USA, 1982-1991. J Rheumatol 27 (2000) 1247-1250
2. Alamanos Y., Papadopoulos N.G., Voulgari P.V., Siozos C., Psychos D.N., Tympanidou M., et al. Epidemiology of psoriatic arthritis in northwest Greece, 1982-2002. J Rheumatol 30 (2003) 2641-2644
3. Taylor W.J. Epidemiology of psoriatic arthritis. Curr Opin Rheumatol 14 (2002) 98-103
4. McHugh N.J., Balachrishnan C., and Jones S.M. Progression of peripheral joint disease in psoriatic arthritis: a 5-yr prospective study. Rheumatology (Oxford) 42 (2003) 778-783
5. Gladman D.D. Psoriatic arthritis. Dermatol Ther 17 (2004) 350-363
6. Sampogna F., Sera F., Abeni D., and IDI Multipurpose Psoriasis Research on Vital Experiences (IMPROVE) Investigators. Measures of clinical severity, quality of life, and psychological distress in patients with psoriasis: a cluster analysis. J Invest Dermatol 122 (2004) 602-607
7. Choi J., and Koo J.Y. Quality of life issues in psoriasis. J Am Acad Dermatol 49 Suppl 2 (2003) S57-S61
8. Rapp S.R., Feldman S.R., Exum M.L., Fleischer Jr. A.B., and Reboussin D.M. Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol 41 3 Pt. 1 (1999) 401-407
9. Spuls P.I., Bossuyt P.M., van Everdingen J.J., Witkamp L., and Bos J.D. The development of practice guidelines for the treatment of severe plaque form psoriasis. Arch Dermatol 134 (1998) 1591-1596
10. Smith C.H., Anstey A.V., Barker J.N., Burden A.D., Chalmers R.J., Chandler D., et al. British Association of Dermatologists guidelines for use of biological interventions in psoriasis 2005. Br J Dermatol 153 (2005) 486-497
11. Kyle S., Chandler D., Griffiths C.E., Helliwell P., Lewis J., McInnes I., et al. Guideline for anti-TNF-alpha therapy in psoriatic arthritis. Rheumatology (Oxford) 44 (2005) 390-397
12. Mease P.J., Goffe B.S., Metz J., VanderStoep A., Finck B., and Burge D.J. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet 356 9227 (2000) 385-390
13. Mease P.J., Kivitz A.J., Burch F.X., Siegel E.L., Cohen S.B., Ory P., et al. Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression. Arthritis Rheum 50 (2004) 2264-2272
14. Antoni C., Dechant C., Hanns-Martin Lorenz P.D., Wendler J., Ogilvie A., Lueftl M., et al. Open-label study of infliximab treatment for psoriatic arthritis: clinical and magnetic resonance imaging measurements of reduction of inflammation. Arthritis Rheum 47 (2002) 506-512
15. Antoni C.E., Kavanaugh A., Kirkham B., Tutuncu Z., Burmester G.R., Schneider U., et al. Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT). Arthritis Rheum 52 (2005) 1227-1236
16. Mease P.J., Gladman D.D., Ritchlin C.T., Ruderman E.M., Steinfeld S.D., Choy E.H., et al. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial. Arthritis Rheum 52 (2005) 3279-3289
17. Antoni C., Krueger G.G., de Vlam K., Birbara C., Beutler A., Guzzo C., et al. Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial. Ann Rheum Dis 64 (2005) 1150-1157
18. Feletar M., Brockbank J.E., Schentag C.T., Lapp V., and Gladman D.D. Treatment of refractory psoriatic arthritis with infliximab: a 12 month observational study of 16 patients. Ann Rheum Dis 63 (2004) 156-161
19. Dougados M., van der Linden S., Juhlin R., Huitfeldt B., Amor B., Calin A., et al. The European Spondylarthropathy Study Group preliminary criteria for the classification of spondylarthropathy. Arthritis Rheum 34 (1991) 1218-1227
20. Taylor W.J., Marchesoni A., Arreghini M., Sokoll K., and Helliwell P.S. A comparison of the performance characteristics of classification criteria for the diagnosis of psoriatic arthritis. Semin Arthritis Rheum 34 (2004) 575-584
21. Ashcroft D.M., Wan Po A.L., Williams H.C., and Griffiths C.E. Clinical measures of disease severity and outcome in psoriasis: a critical appraisal of their quality. Br J Dermatol 141 (1999) 185-191
22. Finlay A.Y. Current severe psoriasis and the rule of tens. Br J Dermatol 152 (2005) 861-867
23. Gladman D.D., Helliwell P., Mease P.J., Nash P., Ritchlin C., and Taylor W. Assessment of patients with psoriatic arthritis: a review of currently available measures. Arthritis Rheum 50 (2004) 24-35
24. Felson D.T., Anderson J.J., Boers M., Bombardier C., Furst D., Goldsmith C., et al., American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 38 (1995) 727-735
25. Prevoo M.L., van't Hof M.A., Kuper H.H., van Leeuwen M.A., van de Putte L.B., and van Riel P.L. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 38 (1995) 44-48
26. Bos J.D., and De Rie M.A. The pathogenesis of psoriasis: immunological facts and speculations. Immunol Today 20 (1999) 40-46
27. Ettehadi P., Greaves M.W., Wallach D., Aderka D., and Camp R.D. Elevated tumour necrosis factor-alpha (TNF-alpha) biological activity in psoriatic skin lesions. Clin Exp Immunol 96 (1994) 146-151
28. Partsch G., Steiner G., Leeb B.F., Dunky A., Broll H., and Smolen J.S. Highly increased levels of tumor necrosis factor-alpha and other proinflammatory cytokines in psoriatic arthritis synovial fluid. J Rheumatol 24 (1997) 518-523
29. Ritchlin C., Haas-Smith S.A., Hicks D., Cappuccio J., Osterland C.K., and Looney R.J. Patterns of cytokine production in psoriatic synovium. J Rheumatol 25 (1998) 1544-1552
30. Hohler T., Kruger A., Schneider P.M., Schopf R.E., Knop J., Rittner C., et al. A TNF-alpha promoter polymorphism is associated with juvenile onset psoriasis and psoriatic arthritis. J Invest Dermatol 109 (1997) 562-565
31. Goedkoop A.Y., Kraan M.C., Teunissen M.B., Picavet D.I., de Rie M.A., Bos J.D., et al. Early effects of tumour necrosis factor alpha blockade on skin and synovial tissue in patients with active psoriasis and psoriatic arthritis. Ann Rheum Dis 63 (2004) 769-773
32. Nikas S.N., Voulgari P.V., Takalou I.P., Katsimbri P., and Drosos A.A. Healing of psoriatic skin lesions and improvement of psoriatic arthritis resistant to immunosuppressive drugs, after infliximab treatment. Ann Rheum Dis 64 (2005) 1665-1667
33. Voulgari P.V., Venetsanopoulou A.I., Epagelis E.K., Alamanos Y., Takalou I., and Drosos A.A. Infliximab in refractory psoriatic arthritis with severe psoriasis: a 2-year experience. Ann Rheum Dis 66 (2007) 270-271
34. Kavanaugh A., Krueger G.G., Beutler A., Guzzo C., Zhou B., Dooley L.T., et al., IMPACT 2 Study Group. Infliximab maintains a high degree of clinical response in patients with active psoriatic arthritis through 1 year of treatment: results from the IMPACT 2 trial. Ann Rheum Dis 66 (2007) 498-505
35. Yazdani-Biuki B., Wohlfahrt K., Mulabecirovic A., Mueller T., Hermann J., Graninger W.B., et al. Long term treatment of psoriatic arthritis with infliximab. Ann Rheum Dis 63 (2004) 1531-1532
36. Brocq O., Roux C.H., Albert C., Breuil V., Aknouche N., Ruitord S., et al. TNFalpha antagonist continuation rates in 442 patients with inflammatory joint disease. Joint Bone Spine 74 (2007) 148-154
37. Temekonidis T.I., Georgiadis A.N., Alamanos Y., Bougias D.V., Voulgari P.V., and Drosos A.A. Infliximab treatment in combination with cyclosporin A in patients with severe refractory rheumatoid arthritis. Ann Rheum Dis 61 (2002) 822-825
38. Voulgari P.V., Alamanos Y., Nikas S.N., Bougias D.V., Temekonidis T.I., and Drosos A.A. Infliximab therapy in established rheumatoid arthritis: an observational study. Am J Med. 118 (2005) 515-520
39. Feldmann M., Elliott M.J., Woody J.N., and Maini R.N. Anti-tumor necrosis factor-alpha therapy of rheumatoid arthritis. Adv Immunol 64 (1997) 283-350
40. Maini R.N., Breedveld F.C., Kalden J.R., Smolen J.S., Davis D., Macfarlane J.D., et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 41 (1998) 1552-1563